Quellis Biosciences emerged from stealth to discover best-in-class new molecules to treat serious rare diseases. The company is optimizing several novel monoclonal antibodies targeting a validated but undisclosed mechanism of action for an undisclosed rare disease. Quellis holds a target-exclusive license to Xencor's Xtend® Fc technology to improve antibody half-life and potentially reduce dose size and frequency. The company was founded in November 2017 by biopharma incubator Viridian LLC with seed financing from Xontogeny LLC and is based in Boston. Its leadership includes founding CEO Jonathan Violin, Ph.D., and Chief Scientific Officer Vahe Bedian, Ph.D., both Partners at Viridian, and its board includes representatives from Xontogeny and the PXV Fund. Quellis closed a $17 million Series A to advance optimization of its lead antibody programs.

Total raised

$17M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2019